Close

Carisma Therapeutics (CARM) to Merge with Ocugen's (OCGN) OrthoCellix Jun 23, 2025 07:30AM
Chardan Capital Markets Starts Monopar Therapeutics (MNPR) at Buy, PT $60 Jun 23, 2025 05:03AM
Lion Group Holding (LGHL) Secures $600M Facility to Launch Hyperliquid (HYPE) Treasury Jun 18, 2025 08:45AM
Eyenovia (EYEN) Announces $50 Million Investment to Launch a Hyperliquid (HYPE token) Cryptocurrency Treasury Reserve Strategy Jun 17, 2025 02:57PM
Chardan Capital Markets Reiterates Buy Rating on Dyne Therapeutics (DYN) Following FDA Update Jun 17, 2025 09:39AM
View Older Stories

Jun 16, 2025 07:05AM Klotho Neurosciences (KLTO) Raises Over $11 Million, Retires All Debt, And Exceeds Nasdaq Stockholders' Equity Requirement
Jun 2, 2025 10:30AM VivoPower (VVPR) and BitGo Partner to Facilitate its Initial $100M XRP Acquisition for Treasury Strategy
Jun 2, 2025 10:21AM BitGo Enters Strategic Partnership with VivoPower (VVPR) to Facilitate its Initial US$100 Million XRP Acquisition for Treasury Strategy
Jun 2, 2025 10:21AM BitGo Enters Strategic Partnership with VivoPower to Facilitate its Initial US$100 Million XRP Acquisition for Treasury Strategy
Jun 2, 2025 08:32AM Classover Holdings (KIDZ) Completes Initial SOL Purchase and Enters into New Purchase Agreement to Sell up to $500M of Notes
Jun 2, 2025 08:30AM Classover Completes Initial SOL Purchase and Enters into New Purchase Agreement to Sell up to $500 Million of Notes to Accelerate SOL Treasury Strategy
May 28, 2025 12:35PM VivoPower (VVPR) Announces XRP-Focused Digital Asset Treasury Strategy and US$121 Million Private Placement Priced at US$6.05 Per Share
May 28, 2025 12:35PM VivoPower Announces XRP-Focused Digital Asset Treasury Strategy and US$121 Million Private Placement Priced at US$6.05 Per Share, Above Last Market Closing Price Under NASDAQ Rules
May 21, 2025 03:43AM Chardan Capital Markets Assumes CleanSpark Inc. (CLSK) at Buy
May 19, 2025 01:12PM Prime Medicine (PRME) PT Lowered to $12 at Chardan Capital Markets
May 12, 2025 03:57PM Chardan Capital Markets Reiterates Buy Rating on CervoMed (CRVO)
May 12, 2025 02:14AM AB Science reports its revenues for the year 2024 and provides an update on its activities
May 8, 2025 05:06AM Chardan Capital Markets Downgrades Seres Therapeutics (MCRB) to Neutral
May 7, 2025 04:30AM Chardan Capital Markets Starts Bright Minds Biosciences Inc. (DRUG) at Buy
May 7, 2025 04:30AM Chardan Capital Markets Starts Praxis Precision Medicines Inc. (PRAX) at Buy
May 7, 2025 04:30AM Chardan Capital Markets Starts Xenon Pharmaceuticals (XENE) at Buy
Apr 29, 2025 01:44PM iBio, Inc. (IBIO) Raises $6.2M Through Warrant Inducement Transaction
Apr 29, 2025 01:43PM iBio Raises $6.2 Million Through Warrant Inducement Transaction
Apr 28, 2025 04:30PM Orchestra BioMed to Participate in Upcoming Institutional Investor Conferences
Apr 23, 2025 04:14AM Chardan Capital Markets Starts Tourmaline Bio (TRML) at Buy
Apr 22, 2025 04:05PM Elutia to Participate in Chardan’s Trending Issues in Drug Development Conference Series on April 29
Apr 16, 2025 08:00AM /C O R R E C T I O N -- Marcum Asia CPAs LLP/
Apr 16, 2025 08:00AM Japan Go IPO Summit Announces Roster of Expert Speakers for Event June 5th in Tokyo
Apr 16, 2025 01:12AM Chardan Capital Markets Starts Korro Bio Inc. (KRRO) at Buy
Apr 14, 2025 09:27AM Kodiak to Go Public Via Business Combination With Ares Acquisition Corporation II (AACT)
Apr 14, 2025 08:00AM Kodiak, a Leading Provider of AI-Powered Autonomous Vehicle Technology, to Go Public Via Business Combination With Ares Acquisition Corporation II
Apr 10, 2025 06:58PM Form X-17A-5 CHARDAN CAPITAL MARKETS For: Dec 31
Apr 9, 2025 11:00AM Centri Announces Sponsors for Capital Conference at Nasdaq on April 22
Apr 9, 2025 06:13AM Chardan Capital Markets Starts Palvella Therapeutics (PVLA) at Buy
Apr 1, 2025 08:06AM Chardan Capital Markets Assumes uniQure BV (QURE) at Buy, PT $38
Mar 27, 2025 08:03AM Chardan Capital Markets Reiterates Neutral Rating on Allurion Technologies (ALUR)
Mar 26, 2025 07:57AM Zura Bio Ltd. (ZURA) PT Lowered to $10 at Chardan Capital Markets
Mar 24, 2025 09:00AM Japan Go IPO Summit Provides Roadmap for Japanese Companies Seeking to List on U.S. Exchanges
Mar 20, 2025 07:00AM Eyenovia Enters into Non-Binding Letter of Intent to Effect Reverse Merger with Betaliq
Mar 20, 2025 06:28AM Prime Medicine (PRME) PT Lowered to $16 at Chardan Capital Markets
Mar 18, 2025 08:53AM Vincerx Pharma (VINC) Announces Non-Binding Letter of Intent for Business Combination with QumulusAI
Mar 18, 2025 08:52AM Vincerx Pharma Announces Non-Binding Letter of Intent for Business Combination with QumulusAI
Mar 17, 2025 07:53AM Chardan Capital Markets Reiterates Buy Rating on Dyne Therapeutics (DYN)
Mar 12, 2025 04:39PM Chardan Capital Markets Upgrades CervoMed (CRVO) to Buy
Mar 4, 2025 04:13PM Passage Bio Inc. (PASG) PT Lowered to $6 at Chardan Capital Markets
Mar 4, 2025 08:07AM Instinct Brothers to Go Public via Merger with Relativity Acquisition Corp (BIOT)
Mar 4, 2025 08:00AM Instinct Brothers Co., Ltd, a Japanese Vertically Integrated Regenerative Medicine & Stem Cell Technology Company, to Go Public via Merger with Relativity Acquisition Corp.
Mar 4, 2025 08:00AM Instinct Brothers Co., Ltd, a Japanese Vertically Integrated Regenerative Medicine & Stem Cell Technology Company, to Go Public via Merger with Relativity Acquisition Corp.
Feb 27, 2025 07:00AM Dragonfly Energy Holdings (DFLI) Announces Corporate Debt Restructuring and Capital Raise
Feb 27, 2025 07:00AM Dragonfly Energy Announces Corporate Debt Restructuring and Capital Raise
Feb 26, 2025 05:00PM Urgently Announces Capital Structure Improvements and Secures up to $20 Million in New Financing
Feb 25, 2025 08:02AM Senti Biosciences (SNTI) Strengthens Leadership Team with Strategic Hires
Feb 25, 2025 08:00AM Senti Bio Strengthens Leadership Team with Strategic Hires
Feb 24, 2025 07:02AM Eyenovia Inc (EYEN) Announces Debt Restructuring Including Amendment to Senior Secured Debt
Feb 24, 2025 07:00AM Eyenovia, Inc. Announces Debt Restructuring Including Amendment to Senior Secured Debt, Improving Cash Runway to Allow for the Evaluation of Strategic Alternatives
View Older Stories